Comparative RNA Quantification of HIV-1 Group M and Non-M... : JAIDS Journal of Acquired Immune Deficiency Syndromes (original) (raw)

Clinical Science

Comparative RNA Quantification of HIV-1 Group M and Non-M With the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR Assays

Sire, Jean-Marie PharmD; Vray, Muriel MSc; Merzouk, Mourad PharmD; Plantier, Jean-Christophe PharmD, PhD; Pavie, Juliette MD; Maylin, Sarah MD, PhD; Timsit, Julie MD; Lascoux-Combe, Caroline MD; Molina, Jean-Michel MD, PhD; Simon, François MD, PhD; Delaugerre, Constance PharmD, PhD

From the *Laboratoire de Virologie, Hôpital Saint-Louis AP-HP, INSERM U941, Université Paris-Diderot, Paris, France; †Unité d'Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France; ‡Laboratoire de Virologie, Centre Hospitalier Universitaire Charles Nicolle, Faculté de Médecine et de Pharmacie, Rouen, France; §Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Louis, Université Paris-Diderot Paris, France; ‖Service des Maladies Sexuellement Transmissibles, Hôpital Saint-Louis, Paris, France; and ¶Service de Médecine Interne, Hôpital Saint-Louis, Université Paris-Diderot, Paris, France.

Received for publication August 6, 2010; accepted November 16, 2010.

Presented in part at the 17th Conference on Retroviruses and Opportunistic Infections, February 16-19, 2010, San Francisco, CA, USA (abstract #940).

The authors have no funding or conflicts of interest to disclose.

Correspondence to: Dr. Constance Delaugerre, PharmD, PhD, Laboratoire de virologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France (e-mail: [email protected]).

Abstract

Background:

A new version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assay (CA/CTM v2.0) has been introduced to overcome the underquantification observed with the first version.

Methods:

We compared the Roche Cobas CA/CTM v2.0 and Abbott RealTime HIV-1 assays for HIV-1 group M and non-M viral load measurement.

Results:

We found a good correlation (r = 0.96) between the 2 techniques for the 260 HIV-1 group M plasma samples tested. The Roche Cobas assay gave significantly higher values than the Abbott assay, and 51 samples (20%) yielded differences greater than 0.5 log10 copies per milliliter. Conversely, 2 samples were more than 0.5 log10 copies per milliliter higher with the Abbott assay than with the Roche Cobas assay. Among the 84 samples with undetectable viral load in the Abbott assay (detection limit 40 copies/mL), 17 (20%) were detectable with the CA/CTM v2.0 assay (detection limit 20 copies/mL), with values ranging from 41 to 897 copies per milliliter. Extrapolation of the Abbott curves led to 10/17 (59%) of these samples being quantifiable. HIV-1 groups O and P were similarly quantified by the two techniques.

Conclusion:

The results of the Roche Cobas CA/CTM v2.0 and Abbott RealTime HIV-1 assays correlate well. The new version of the CA/CTM assay shows improved sensitivity. Nevertheless, the 2 assays differ by more than 0.5 log10 copies per milliliter for some samples.